Editorial: Updates on combination therapy for lung cancer volume II.

This summary provides an update on combination therapy for lung cancer, a leading cause of death worldwide. It discusses advancements in immune-checkpoint inhibitors and targeted agents that have improved survival rates. The article explores challenges in treatment sequencing, the role of anti-angiogenic drugs, and the efficacy of chemo-immunotherapy. It also highlights the use of computational biology to identify new targets for cancer treatment. [Extracted from the article]